Published in Blood on September 26, 2011
Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs (2012) 1.28
Mechanisms of action of CD20 antibodies. Am J Cancer Res (2012) 1.15
Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients. Leukemia (2013) 0.86
Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells. Haematologica (2013) 0.85
A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies. J Hematol Oncol (2014) 0.85
Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors. Haematologica (2015) 0.84
Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia. Biologics (2015) 0.80
A Short History of the B-Cell-Associated Surface Molecule CD40. Front Immunol (2014) 0.80
Synergistic apoptotic response between valproic acid and fludarabine in chronic lymphocytic leukaemia (CLL) cells involves the lysosomal protease cathepsin B. Blood Cancer J (2013) 0.79
Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspective. Ther Adv Hematol (2015) 0.76
CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies. Invest New Drugs (2016) 0.76
7th cancer scientific forum of theCancéropôle Lyon Auvergne Rhône-Alpes: March 20-21, 2012, Lyon, France. MAbs (2012) 0.76
A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies. Adv Ther (2016) 0.75
Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia. Clin Interv Aging (2015) 0.75
Lysosomotropic agents selectively target chronic lymphocytic leukemia cells due to altered sphingolipid metabolism. Leukemia (2015) 0.75
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (2004) 24.42
Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry A (2008) 4.71
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood (2012) 4.17
Large-scale identification of N-terminal peptides in the halophilic archaea Halobacterium salinarum and Natronomonas pharaonis. J Proteome Res (2007) 3.30
Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines. Mol Cancer Res (2007) 3.21
STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo. Gastroenterology (2006) 3.05
Interleukin 6/gp130-dependent pathways are protective during chronic liver diseases. Hepatology (2003) 2.68
Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther (2012) 2.63
miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood (2008) 2.58
Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci U S A (2004) 2.46
Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol (2008) 2.32
CD20 deficiency in humans results in impaired T cell-independent antibody responses. J Clin Invest (2009) 2.15
Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood (2011) 2.13
CD70+ antigen-presenting cells control the proliferation and differentiation of T cells in the intestinal mucosa. Nat Immunol (2005) 2.02
Apoptosis threshold set by Noxa and Mcl-1 after T cell activation regulates competitive selection of high-affinity clones. Immunity (2010) 1.98
Lethal T cell immunodeficiency induced by chronic costimulation via CD27-CD70 interactions. Nat Immunol (2002) 1.97
WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization. J Biol Chem (2006) 1.94
The Noxa/Mcl-1 axis regulates susceptibility to apoptosis under glucose limitation in dividing T cells. Immunity (2006) 1.86
Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A (2011) 1.85
Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling. J Clin Invest (2012) 1.85
c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches. Blood (2008) 1.79
p53 contains large unstructured regions in its native state. J Mol Biol (2002) 1.75
Human NK cells can control CMV infection in the absence of T cells. Blood (2008) 1.75
A case of meningoencephalitis by the relapsing fever spirochaete Borrelia miyamotoi in Europe. Lancet (2013) 1.73
Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy. J Invest Dermatol (2011) 1.71
Enhanced formation and survival of CD4+ CD25hi Foxp3+ T-cells in chronic lymphocytic leukemia. Leuk Lymphoma (2009) 1.65
Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics (2003) 1.63
The N-terminal domain of p53 is natively unfolded. J Mol Biol (2003) 1.62
Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood (2007) 1.60
Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther (2013) 1.60
Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood (2002) 1.59
Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells. Br J Haematol (2010) 1.57
Idiopathic CD4+ T lymphopenia without autoimmunity or granulomatous disease in the slipstream of RAG mutations. Blood (2011) 1.53
Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood (2002) 1.50
CMV-specific CD8+ T-cell function is not impaired in chronic lymphocytic leukemia. Blood (2013) 1.49
Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. Blood (2006) 1.47
Effects of allogeneic leukocytes in blood transfusions during cardiac surgery on inflammatory mediators and postoperative complications. Crit Care Med (2010) 1.47
Tumor rejection induced by CD70-mediated quantitative and qualitative effects on effector CD8+ T cell formation. J Exp Med (2004) 1.46
Conformational ordering of biomolecules in the gas phase: nitrogen collision cross sections measured on a prototype high resolution drift tube ion mobility-mass spectrometer. Anal Chem (2014) 1.45
Flt1 acts as a negative regulator of tip cell formation and branching morphogenesis in the zebrafish embryo. Development (2011) 1.44
Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue. J Immunol (2010) 1.44
Interleukin-6/glycoprotein 130-dependent pathways are protective during liver regeneration. J Biol Chem (2002) 1.42
Strong selection of virus-specific cytotoxic CD4+ T-cell clones during primary human cytomegalovirus infection. Blood (2006) 1.40
Failing immune control as a result of impaired CD8+ T-cell maturation: CD27 might provide a clue. Trends Immunol (2002) 1.36
Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia. Clin Cancer Res (2011) 1.35
APRIL promotes B-1 cell-associated neoplasm. Cancer Cell (2004) 1.34
Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood (2013) 1.34
Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. Mol Cancer Ther (2011) 1.33
Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica (2008) 1.33
Lack of Epstein-Barr virus- and HIV-specific CD27- CD8+ T cells is associated with progression to viral disease in HIV-infection. AIDS (2002) 1.28
Characterization of CD4+ memory T cell responses directed against common respiratory pathogens in peripheral blood and lung. J Infect Dis (2007) 1.27
Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy. Clin Cancer Res (2013) 1.26
Ultrasensitive in situ visualization of active glucocerebrosidase molecules. Nat Chem Biol (2010) 1.26
B cells are crucial for both development and maintenance of the splenic marginal zone. J Immunol (2004) 1.23
Neural guidance molecules, tip cells, and mechanical factors in vascular development. Cardiovasc Res (2008) 1.22
Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells. Haematologica (2010) 1.17
In vivo dynamics of stable chronic lymphocytic leukemia inversely correlate with somatic hypermutation levels and suggest no major leukemic turnover in bone marrow. Cancer Res (2008) 1.16
Loss of EBNA1-specific memory CD4+ and CD8+ T cells in HIV-infected patients progressing to AIDS-related non-Hodgkin lymphoma. Blood (2005) 1.16
GITR triggering induces expansion of both effector and regulatory CD4+ T cells in vivo. J Immunol (2009) 1.15
The costimulatory molecule CD27 maintains clonally diverse CD8(+) T cell responses of low antigen affinity to protect against viral variants. Immunity (2011) 1.15
Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol (2011) 1.14
CD27-CD70 interactions sensitise naive CD4+ T cells for IL-12-induced Th1 cell development. Int Immunol (2007) 1.14
Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity. J Immunol (2014) 1.13
Whole-genome scanning by array comparative genomic hybridization as a clinical tool for risk assessment in chronic lymphocytic leukemia. J Mol Diagn (2008) 1.13
Human sprouty 4, a new ras antagonist on 5q31, interacts with the dual specificity kinase TESK1. Eur J Biochem (2002) 1.13
Lack of gp130 expression in hepatocytes promotes liver injury. Gastroenterology (2003) 1.12
Cutting Edge: Distinct NK receptor profiles are imprinted on CD8 T cells in the mucosa and periphery during the same antigen challenge: role of tissue-specific factors. J Immunol (2007) 1.12
BclxL changes conformation upon binding to wild-type but not mutant p53 DNA binding domain. J Biol Chem (2009) 1.12
The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood (2004) 1.11
Array CGH analysis of chronic lymphocytic leukemia reveals frequent cryptic monoallelic and biallelic deletions of chromosome 22q11 that include the PRAME gene. Leuk Res (2008) 1.11
Immune activation modulates hematopoiesis through interactions between CD27 and CD70. Nat Immunol (2005) 1.11
High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. Br J Haematol (2008) 1.10
Cellular immune therapy for chronic lymphocytic leukemia. Blood (2007) 1.09
Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial. Haematologica (2007) 1.09
Cutting edge: HLA-B27 acquires many N-terminal dibasic peptides: coupling cytosolic peptide stability to antigen presentation. J Immunol (2006) 1.09
p53--a natural cancer killer: structural insights and therapeutic concepts. Angew Chem Int Ed Engl (2006) 1.08
Quantitative profiling of the membrane proteome in a halophilic archaeon. Mol Cell Proteomics (2006) 1.08
Varicellovirus UL 49.5 proteins differentially affect the function of the transporter associated with antigen processing, TAP. PLoS Pathog (2008) 1.08
A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and anti-angiogenic efficacy and superior side effect profile compared to Pan-Angiopoietin-1/-2 inhibitors. PLoS One (2013) 1.07
Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies. J Inherit Metab Dis (2011) 1.07
GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present. Leuk Lymphoma (2013) 1.05
Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas. Blood (2011) 1.05